Monte Rosa Therapeutics, Inc. GLUE Stock Forecast
AI-powered price prediction and analysis for Monte Rosa Therapeutics, Inc. · Alpha · vs marketSwitch to Total
See GLUE's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (GLUE) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
- Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
- Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q3 Collaboration Revenue $54.4M, vs. FactSet Est of $33.9M
- Sign up free to read all 9 articles →
Where GLUE sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| GLUE Monte Rosa Therapeutics, Inc. | $874M | – | |
| AMGN Amgen Inc | $248.84B | 26.7x | |
| GILD Gilead Sciences, Inc. | $207.84B | – | |
| MRNA Moderna, Inc. | $96.40B | – | |
| ARGX Argenx Se | $55.37B | 23.5x | |
| RVMD Revolution Medicines, Inc. | $38.08B | – | |
| BIIB Biogen Inc. | $36.06B | 105.1x | |
| BNTX Biontech Se | $21.71B | 2.2x | |
| EXEL Exelixis, Inc. | $16.77B | 24.7x | |
| NBIX Neurocrine Biosciences Inc | $16.24B | 23.4x | |
| HALO Halozyme Therapeutics, Inc. | $13.96B | 24.9x | |
| TECH Bio-Techne Corp | $11.41B | 62.6x | |
| QGEN Qiagen N.V. | $11.03B | 36.1x | |
| KYMR Kymera Therapeutics, Inc. | $10.94B | – | |
| RGEN Repligen Corp | $10.77B | – | |
| PCVX Vaxcyte, Inc. | $9.21B | – | |
| KRYS Krystal Biotech, Inc. | $8.90B | 40.8x | |
| IBRX Immunitybio, Inc. | $8.49B | – | |
| TWST Twist Bioscience Corp | $7.56B | – | |
| IMVT Immunovant, Inc. | $5.86B | – | |
| CGON Cg Oncology, Inc. | $5.74B | – | |
| KOD Kodiak Sciences Inc. | $5.72B | – | |
| SRRK Scholar Rock Holding Corp | $5.54B | – | |
| CRSP Crispr Therapeutics Ag | $4.70B | – | |
| ADPT Adaptive Biotechnologies Corp | $4.28B | – | |
| RLAY Relay Therapeutics, Inc. | $3.73B | – | |
| IOVA Iovance Biotherapeutics, Inc. | $3.51B | – | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | – | |
| DNLI Denali Therapeutics Inc. | $3.15B | – | |
| ADMA Adma Biologics, Inc. | $2.96B | 19.7x | |
| BEAM Beam Therapeutics Inc. | $2.67B | 369.6x | |
| VCEL Vericel Corp | $2.65B | 105.7x | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.18B | – | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.13B | – | |
| LIFE Atyr Pharma Inc | $2.08B | – | |
| BCRX Biocryst Pharmaceuticals Inc | $1.95B | – | |
| REPL Replimune Group, Inc. | $1.90B | – | |
| VIR Vir Biotechnology, Inc. | $1.86B | – | |
| MAZE Maze Therapeutics, Inc. | $1.81B | – | |
| MESO Mesoblast Ltd | $1.81B | – | |
| ALVO Alvotech | $1.62B | – | |
| NVAX Novavax Inc | $1.61B | 108.7x | |
| IMCR Immunocore Holdings Plc | $1.46B | – | |
| TSHA Taysha Gene Therapies, Inc. | $1.33B | – | |
| VOR Vor Biopharma Inc. | $1.15B | – | |
| CGEM Cullinan Therapeutics, Inc. | $1.01B | – | |
| ODTX Odyssey Therapeutics, Inc. | $907M | – | |
| IMTX Immatics N.V. | $829M | – | |
| MGTX Meiragtx Holdings Plc | $817M | 11.1x | |
| PRME Prime Medicine, Inc. | $807M | – | |
| SANA Sana Biotechnology, Inc. | $700M | – | |
| SLBT Sl Science Holding Ltd | $679M | – | |
| DNA Ginkgo Bioworks Holdings, Inc. | $671M | – | |
| SLDB Solid Biosciences Inc. | $663M | – | |
| AURA Aura Biosciences, Inc. | $657M | – | |
| FDMT 4d Molecular Therapeutics, Inc. | $621M | – | |
| DBVT Dbv Technologies S.A. | $616M | – | |
| CADL Candel Therapeutics, Inc. | $615M | – | |
| VALN Valneva Se | $551M | – | |
| ENTX Entera Bio Ltd. | $518M | 9.1x |
FAQ
Is Monte Rosa Therapeutics, Inc. a good stock to buy?
Our AI analyzes Monte Rosa Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Monte Rosa Therapeutics, Inc. predictions?
For GLUE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Monte Rosa Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Monte Rosa Therapeutics, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.